Chagas disease / leishmaniasis
Chagas disease / leishmaniasis
| iNTRODB
(Integrated Neglected TROpical disease DataBase) |
Astellas created the world's first integrated database for NTDs Drug-discovery research named iNTRODB (Integrated Neglected TROpical disease The iNTRODB includes information on the following
The iNTRODB includes information on all protein-coding genes in genomes of three trypanosome species which cause Leishmaniasis, Chagas' disease and African trypanosomiasis It helps researchers to identify and choose promising drug target proteins by providing various information Every researcher can freely use this database and therefore the Every researcher can freely use this database and therefore the iNTRODB can accelerate drug discovery research for NTDs across the world. |
|---|---|
| Development of medicine for treating Chagas disease | Eisai and the Drugs for Neglected Disease initiative (Headquarters: Geneva, Switzerland, "DNDi"), an independent non-profit organization, entered Eisai and the Drugs for Neglected Disease initiative (Headquarters: Geneva, Switzerland, "DNDi"), an independent non-profit organization, entered a collaboration for the clinical development of E1224, aiming to develop a new treatment. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Eisai is part of a GHIT Fund-sponsored program to screen for candidate compounds for treating malaria, leishmaniasis and Chagas disease. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Shionogi is also engaged in a GHIT Fund-sponsored program for searching out drug candidates for treating leishmaniasis and Chagas disease. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Daiichi Sankyo is engaged in the GHIT-funded screening program for NTDs (Leishmaniasis and Chagas disease) with its own small molecules and natural The company is also engaged in the joint research to optimize its lead compounds for Chagas disease based on the promising compounds The company is also engaged in the joint research to optimize its lead compounds for Chagas disease based on the promising compounds. |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Astellas engages in GHIT Fund-sponsored screening programs to find drug candidates for the treatment of tuberculosis and malaria. Astellas also engages in a GHIT Fund-sponsored Hit-to-Lead program to find lead compounds for the treatment of NTDs (leishmania). Astellas also engages in a GHIT Fund-sponsored Hit-to-Lead program to find lead compounds for the treatment of NTDs (leishmaniasis and Chagas disease). Astellas also engages in a GHIT Fund-sponsored Hit-to-Lead program to find lead compounds for the treatment of NTDs (leishmaniasis and Chagas disease). |
| Screening programs for containing infections in developing countries (GHIT Fund programs) | Mitsubishi Tanabe Pharma is part of a GHIT Fund-sponsored program to screen for candidate compounds for treating malaria, leishmaniasis and Chagas disease, and provides its original library of compounds in the program. Astellas provides its original library of compounds in the program. |